title: Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis.
abstract: It has been postulated that prostatic carcinogenesis is androgen dependent and that androgens mediate their effects primarily through epithelial cells; however, definitive proof of androgen hormone action in prostate cancer (PRCA) progression is lacking. Here we demonstrate through genetic loss of function experiments that PRCA progression is androgen dependent and that androgen dependency occurs via prostatic stromal androgen receptors (AR) but not epithelial AR. Utilizing tissue recombination models of prostatic carcinogenesis, loss of AR function was evaluated by surgical castration or genetic deletion. Loss of AR function prevented prostatic carcinogenesis, malignant transformation and metastasis. Tissue-specific evaluation of androgen hormone action demonstrated that epithelial AR was not necessary for PRCA progression, whereas stromal AR was essential for PRCA progression, malignant transformation and metastasis. Stromal AR was not necessary for prostatic maintenance, suggesting that the lack of cancer progression due to stromal AR deletion was not related to altered prostatic homeostasis. Gene expression analysis identified numerous androgen-regulated stromal factors. Four candidate stromal AR-regulated genes were secreted growth factors: fibroblast growth factors-2, -7, -10 and hepatocyte growth factor which were significantly affected by androgens and anti-androgens in stromal cells grown in vitro. These data support the concept that androgens are necessary for PRCA progression and that the androgen-regulated stromal microenvironment is essential to carcinogenesis, malignant transformation and metastasis and may serve as a potential target in the prevention of PRCA.
authors.affiliation: University of Wisconsin Carbone Cancer Center, Department of Urology, University of Wisconsin, Madison, WI 53705, USA.
authors.forename: Emily A
authors.initials: EA
authors.lastname: Ricke
authors.forename: Karin
authors.initials: K
authors.lastname: Williams
authors.forename: Yi-Fen
authors.initials: YF
authors.lastname: Lee
authors.forename: Suzana
authors.initials: S
authors.lastname: Couto
authors.forename: Yuzhuo
authors.initials: Y
authors.lastname: Wang
authors.forename: Simon W
authors.initials: SW
authors.lastname: Hayward
authors.forename: Gerald R
authors.initials: GR
authors.lastname: Cunha
authors.forename: William A
authors.initials: WA
authors.lastname: Ricke
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage; D000728:Androgens / Q000502:physiology*; D000818:Animals; D002471:Cell Transformation, Neoplastic; D018450:Disease Progression; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000503:physiopathology; D011944:Receptors, Androgen / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D011944:Receptors, Androgen